# A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)

> **NCT00944671** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Consumer and Personal Products Worldwide** · enrollment: 24 (actual)

## Conditions studied

- Heartburn

## Interventions

- **DRUG:** famotidine (+) calcium carbonate (+) magnesium hydroxide tablet
- **DRUG:** Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water
- **DRUG:** Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water

## Key facts

- **NCT ID:** NCT00944671
- **Lead sponsor:** Johnson & Johnson Consumer and Personal Products Worldwide
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00944671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00944671, "A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00944671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*